alexa Clinical Trial Performance in Metastatic Colorectal Can

Journal of Cancer Clinical Trials
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary

Clinical Trial Performance in Metastatic Colorectal Cancer: An Evaluation of Participating Centers in the CAIRO studies of the Dutch Colorectal Cancer Group.

Lotte Keikes1*, Linda Mol2, Martijn G.H. van Oijen3, Miriam Koopman4, Cornelis J. A. Punt1, and Petronella B Ottevanger5

1Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands

2Clinical Trial Center, Comprehensive Cancer Centre, Nijmegen, The Netherlands

3Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands

4Department of Medical Oncology, University Medical Centre, Utrecht, The Netherlands

5Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

*Corresponding Author:
Lotte Keikes
Academic Medical Center, Department of Medical Oncology
Meibergdreef 9, 1105AZ Amsterdam, The Netherlands
Tel: +31205665955
Fax: +31206919743
E-mail: [email protected]

Received date: February 03, 2017; Accepted date: February 23, 2017; Published date: February 28, 2017

Citation: Keikes L, Mol L, Oijen MGHv, Koopman M, Punt CJA, et al. (1) Clinical Trial Performance in Metastatic Colorectal Cancer: An Evaluation of Participating Centers in the CAIRO Studies of the Dutch Colorectal Cancer Group. J Cancer Clin Trials 2: 126.

Copyright: © 2017 Keikes L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Objective: High quality clinical trials are essential for further improvement of treatment strategies for prolonged survival and reliable evidence-based outcomes. However, there are no defined standards for the quality of clinical trial performance. The aim of this study is to examine and compare clinical trial performance with a composite score between (different types of) hospitals, to identify potentially predicting factors for a high trial performance and examine a learning curve in composite performance scores between early compared to subsequent included patients.

Methods: We evaluated trial performance in three large phase 3 randomized clinical trials in metastatic colorectal cancer (CAIRO studies of the Dutch Colorectal Cancer Group, total n=2131) with a newly introduced composite score, consisting of stratification errors, major protocol violations, number of included ineligible patients, and reporting of serious adverse events (SAE) on hospital and patient level. These data were supplemented with a hospital survey containing questions about number of beds, oncologists and research nurses. A logistic regression was performed to identify factors associated with better trial performance (3-4 points).

Results: We observed variation in trial performance between 84 participating hospitals. However, no differences in performance between hospital categories (university, teaching and regional hospitals) were identified and none of the examined variables could be linked to a high composite performance score. In top 10 ranking hospitals with highest inclusion rates, trial performance on patient level was significantly lower in the first three inclusions compared to subsequent patients..

Conclusions: Trial performance was comparable between different types of hospitals and no factors were able to predict a high composite trial performance score. In the highest including hospitals we identified a learning curve for trial performance. We therefore recommend increased support during the first patient inclusions in participating centres in order to improve trial performance. Our composite score could be used as a quality metric for trial performance for individually based hospital evaluation.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords